EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

YouTube ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò


[SIDDS 2016]

ÀϽÃ: 2016³â 11¿ù 24ÀÏ - 25ÀÏ

Àå¼Ò: ±×·£µåÈúÆ° È£ÅÚ


1. Gastric cancer sympotium

1) Mechanism for H. pylori-induced genetic instability in gastric cancer development - Tsutomu Chiva (Japan)

2) Epigenetic and genetic alteration: MSI and EMT - Kyoung-Mee Kim (Korea)

"An important source of plasticity is the EMT (Epithelial-mesenchymal transition). EMT and MET (mesenchymal-epithelial transition) provide a framework through which solid cancers can disseminate and colonize distant sites.

EMT is a process by wich epithelial cells lose their cell polarity and cell-cell adhesion, and gain migratory and invasive properties to become mesechymal stem cells; these are multipotent stromal cells that can differentiate into a variety of cell types. EMT is a biologic process that allows a polarized epithelial cell, which normally interacts with basement membrane via its basal surface, to undergo multiple biological changes that enable it to assue a mesenchymal cell phenotype, which includes enhanced migratory capacity, invasiveness, elevated resistance to apoptosis, and greatly increased production of ECM components. The completion of an EMT is signaled by the degradation of underlying basement membrane and the formation of a mesenchymal stem cell that can migrate away from the epithelial layer in which it originated. A number of distinct molecular processes are engaged in order to initiate an EMT and enable it to reach completion.

The identification of the sinaling pathway that lead to activation of EMT during disease processes will provide new insights into the plasticity of cellular phenotypes and possible therapeutic interventions."

3) Microbiota in gastric cancer - Quanjian Dong (China)

4) Genomic instability in gastric cacner - Byung-Wook Kim (Korea)


2. Treatment of H. pylori (free paper oral presentation)

1) 7 day bismuth-based quadruple therapy vs 14 day moxifloxacin based triple therapy. ±è¼ºÀº (°í½Å´ë)

AnalysisBismuth quatruple
(14 days)
Moxifloxacin triple
(7 days)
ITT75.4%58.5%
PP93.6%73.8%

1Â÷ Á¦±ÕÄ¡·á ½ÇÆРȯÀÚ¿¡¼­ 7 day bismuth-based quadruple therapy°¡ ´õ ÁÁ´Ù´Â °á·ÐÀ̾ú½À´Ï´Ù.

2) Triple therapy vs sequential therapy for first-line Hp eradication. ÀåÁö¿µ (ÀÌÈ­¿©´ë)

AnalysisTriple therapy
(firstline 7days)
Sequential therapy
(firstline)
ITT64.3%74.5%
PP81.9%90.3%

Sequential therapyÀÇ Á¦±ÕÀ²ÀÌ ´õ ³ô¾Ò½À´Ï´Ù.

3) High and frequent doses of dexlansoprazole and amoxicillin. ¹ÚÇýÀ± (°æºÏ´ë)

Amoxicillin 750 mg and dexlansoprazole 30 mg 4 times a day for 14 days

Á¦±Õ ¼º°ø·üÀº ITT ºÐ¼®¿¡¼­ 52.0%, PP ºÐ¼®¿¡¼­ 68.4%¿´½À´Ï´Ù.

4) Hp eradication and type 2 DM. ³²½ÂÁÖ (°­¿ø´ë)

º° Â÷ÀÌ°¡ ¾ø´Ù´Â °á·ÐÀ̾ú½À´Ï´Ù.



© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.